Wecome Pharmaceutical Co Ltd (300878) — Cash Flow-to-Debt Ratio
Wecome Pharmaceutical Co Ltd (300878) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥-1.42 Million could theoretically repay 0% of its total liabilities (CN¥458.37 Million) in one year. Check Wecome Pharmaceutical Co Ltd (300878) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wecome Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Wecome Pharmaceutical Co Ltd across 12 annual periods. Also explore Wecome Pharmaceutical Co Ltd (300878) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Wecome Pharmaceutical Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Wecome Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Wecome Pharmaceutical Co Ltd (300878) total market value.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | CN¥-27.17 Million | CN¥478.50 Million | ▼ -162.3% |
| 2023 | 0.09x | CN¥58.29 Million | CN¥639.23 Million | ▼ -68.8% |
| 2022 | 0.29x | CN¥146.57 Million | CN¥502.25 Million | ▲ +222.5% |
| 2021 | -0.24x | CN¥-67.74 Million | CN¥284.28 Million | ▼ -236.0% |
| 2020 | 0.18x | CN¥42.81 Million | CN¥244.39 Million | ▼ -44.7% |
| 2019 | 0.32x | CN¥112.76 Million | CN¥356.02 Million | ▼ -25.8% |
| 2018 | 0.43x | CN¥105.57 Million | CN¥247.29 Million | ▲ +155.6% |
| 2017 | 0.17x | CN¥29.00 Million | CN¥173.68 Million | ▼ -82.6% |
| 2016 | 0.96x | CN¥100.15 Million | CN¥104.25 Million | ▲ +197.8% |
| 2015 | 0.32x | CN¥29.63 Million | CN¥91.84 Million | ▼ -33.5% |
| 2014 | 0.49x | CN¥46.01 Million | CN¥94.82 Million | ▲ +35.9% |
| 2013 | 0.36x | CN¥25.98 Million | CN¥72.78 Million | — |